The assessment of endogenous glucose production and insulin-stimulated glucose disposal in type 2 diabetes patients using a euglycemic insulin clamp technique with [6,6-2D2]glucose infusion, non-randomized intergroup trial

The assessment of endogenous glucose production and insulin-stimulated glucose disposal in type 2 diabetes patients using a euglycemic insulin clamp technique with [6,6-2D2]glucose infusion, non-randomized intergroup trial - Endogenous glucose production and insulin-stimulated glucose disposal in type 2 diabetes patients.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016259

Enrollment

Registered

2015-01-19

Start date

2015-01-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Until March 31, 2018.Type 2 diabetes patients with fatty liver and obesity undergo a euglycemic insulin clamp technique once. Until March 31, 2018. Type 2 diabetes patients without fatty liver and ob

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hospitalized type 2 diabetes patients. 2) Age is over 20 years and less than 80 years. 3) Patients who can undergo euglycemic insulin clamp technique within seven days of admission. 4) Patients with CAP(controlled attention parameter) > 232.5 dB/m and BMI(body mass index) > 25 kg/m2, or with CAP < 232.5 dB/m and BMI < 25 kg/m2. 5) Patients who obtained document agreement by free will of themselves on understanding after enough explanation when participating about examination is received.

Exclusion criteria

Exclusion criteria: 1) Patients with known bleeding disorders. 2) Type 1 diabetes and secondary diabetes patients. 3) Patients with severe renal disease(s-Cre > 2.0 mg/dl). 4) Patients with severe liver disease (AST or ALT > 100 IU/L). 5) Patients who are unable to be responsible for informed consent due to severe psychiatric disease. 6) Excessive common custom drinker (alcohol > 100 ml/day). 7) Patients who have a history of hypersensitivity. 8) Pregnant or possibly pregnant women. 9) Women on lactation. 10) In addition, patients who were judged inappropriate by an attendant physician.

Design outcomes

Primary

Measure	Time frame
Endogenous glucose production and insulin-stimulated glucose disposal.	—

Secondary

Measure	Time frame
1) Suppression of endogenous glucose production by insulin. 2) Plasma glucose, plasma insulin, C-peptide and free fatty acid. 3) The association of fasting plasma glucose, HbA1c, HOMA-IR, HOMA-beta, CPI, hepatic function, blood-cholesterol level and hematological value with endogenous glucose production and insulin-stimulated glucose disposal. 4) Safety	—

Countries

Japan

Contacts

Public ContactAi Morita

Tokyo University Department of Diabetes and Endocrinology

imo33edo@gmail.com03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026